Seqens has been involved in the small-scale production of potent compounds for many years. As an element of our growth strategy, the Company was seeking an opportunity to construct a potent unit at one of our network sites in Europe or the USA — in 2018, this plan officially came to fruition.

NEW POTENT DRUG MANUFACTURING UNIT

The facility consists of two units, located in the same building, a smaller one named UPP10 and a larger one named UPP30, to handle production of potent molecules from tens of kilograms to several hundreds. The initial capacity will be 10–15 tons per year.

The potent unit will maintain a maximum level of particles in the working environment of 100 ng/m3. This level will allow for the production of Safebridge category 3 potent compounds — molecules with occupational exposure limits ranging from approximately 30 ng/m3 to 10 μg/m3.

The modular unit is specifically designed to be flexible and allow for future investments as customers needs evolve.

The construction, located outside Paris, France, started at the beginning of the year, will be completed by fall 2019.

Our location

Address 35 Avenue Jean Jaurès
92390 Villeneuve-la-Garenne
Business Line Contract Manufacturing & Proprietary APIs
Phone +33 1 34 78 87 87
Market Pharmaceutical
Mail info.cdmo@seqens.com
More information

Capabilities: 

  • 70 m³ of GMP reactors
  • 100 L – 8 000 L vessels

Flagship technologies: 

  • Optical resolution
  • Enzymatic hydrolysis
  • Enantioselective reduction
  • Low-temperature reactions (-80 °C)
  • Specific reduction
  • Hydrogenation (40 bar)
  • Organomagnesium compounds
  • Thin-layer distillation